Table 4.

Neurodevelopmental testing.

	Total cohort (n = 67) 2011–2020	Before STEP (n = 36) 2011–2016	After STEP (n = 31) 2017–2020	p-value
Complete	37 (48%)	14 (38.8%)	23 (74.2%)	<0.001
Incomplete	8 (12%)	2 (5.6%)	6 (19.3%)
Not referred	22 (32.8%)	20 (55.6%)	2 (6.5%)
For patients with complete neurodevelopmental testing
Time-appropriate	32 (86.5%)	10 (71.4%)	22 (95.6%)	0.03
Not time-appropriate	5 (13.5%)	4 (28.6%)	1 (4.4%)

^*10 patients were excluded from the analysis due to delays in obtaining hospital appointments during the beginning of the pandemic.